V
Vistin Pharma ASA
OSE:VISTN
Vistin Pharma ASA
OSE:VISTN
Price:
22
NOK
2.33%
Market Closed
Market Cap:
kr975.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
NO |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
CH |
|
teno.Holdings Co Ltd
TSE:7037
|
JP |
|
Locondo Inc
TSE:3558
|
JP |
|
Guangdong Shenling Environmental Systems Co Ltd
SZSE:301018
|
CN |
|
M
|
Menora Mivtachim Holdings Ltd
TASE:MMHD
|
IL |
|
K
|
Kardan Real Estate Enterprise and Development Ltd
TASE:KARE
|
IL |
|
SKF AB
STO:SKF B
|
SE |
|
I
|
Icade SA
OTC:CDMGF
|
FR |
|
Shanghai Baolijia Chemical Co Ltd
SZSE:301037
|
CN |
|
G
|
Gama Management and Clearing Ltd
TASE:GMA
|
IL |
|
Emperor Energy Ltd
ASX:EMP
|
AU |
|
F
|
FRX Innovations Inc
XTSX:FRXI
|
CA |
|
China National Chemical Engineering Co Ltd
SSE:601117
|
CN |
|
E
|
Europen Endustri Insaat Sanayi ve Ticaret AS
IST:EUREN.E
|
TR |
|
Visteon Corp
NASDAQ:VC
|
US |
Multiples-Based Value
The Multiples-Based Value for Vistin Pharma ASA (VISTN) under the Base Case is hidden NOK. Compared with the current market price of 22 NOK, the stock appears hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VISTN Multiples-Based Value
LOCKED
Multiples Across Competitors
VISTN Competitors Multiples
Vistin Pharma ASA Competitors
Vistin Pharma ASA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NO |
V
|
Vistin Pharma ASA
OSE:VISTN
|
975.6m NOK | 2.2 | 13.1 | 8.3 | 10.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
